Merck & Co. Partners with Guardant Health on Multi-Year Oncology Collaboration for Biomarker-Driven Cancer Therapies

Guardant Health and Merck announced a multi-year strategic collaboration on January 19 to integrate Guardant’s liquid and tissue biopsy tests, including the Infinity Smart platform, into Merck’s global oncology clinical trials for patient screening and enrollment.1 2 3

The partnership focuses on developing novel companion diagnostics (CDx) for Merck’s oncology therapies, potentially including new indications for Keytruda, and co-commercializing approved drug-diagnostic combinations in the US, Europe, UK, and Asia-Pacific.1 2 3 4

Guardant Infinity Smart is a multiomic platform analyzing genomic alterations and epigenomic methylation for higher sensitivity in detecting minimal residual disease and therapy response.1

Helmy Eltoukhy, Guardant Health chairman and co-CEO, stated the collaboration brings molecular clarity to oncology trials to reach the right patients faster.2 3 4

This deal positions Guardant as a key infrastructure partner for Big Pharma, following similar partnerships like with Pfizer.1

Sources:

1. https://grafa.com/en/news/united-states/gh-merck-oncology-collaboration

2. https://www.stocktitan.net/news/GH/guardant-health-announces-multi-year-strategic-collaboration-s3ztqmvihn0n.html

3. https://www.fiercebiotech.com/medtech/guardant-health-pens-merck-co-cancer-collab-next-gen-tests-and-companion-diagnostics

4. https://www.medicaldevice-network.com/news/guardant-msd-collaborate-diagnostics-development/

Sources:

Leave a Reply Cancel reply